Day 3 – 23 September 2021


Interactive poster session 5
Moderators: Dita Maixnerová (Czech Republic) & Hitoshi Suzuki (Japan)

Clinicopathological prognostic stratification for renal survival in the Japanese IgA nephropathy prospective cohort study (J-IGACS)
Kentaro Koike (Japan)

Clinicopathological features, risk factors, and outcomes of immunoglobulin A nephropathy associated with hepatitis B virus infection
Jiachuan Xiong (China)

Long-term outcomes of IgA nephropathy patients with less than 25% crescents and mild proteinuria
Qing Jia (China)

FcαRI-mediated neutrophil activation contributed to the pathogenesis of IgA vasculitis with nephritis
Qianqian Li (China)

WITHDRAWN The Comparison of Efficacy and Safety in High-Risk IgA Nephropathy with Low-dose and Full-dose Prednisone Treatment ---A Prospective Randomized Controlled Trial
Yan Li (China)

09:00–09:05 Break
09:05–10:05 Industry Symposium 5
10:05–10:15 Coffee Break

Plenary Session 9
Paediatric IgAN Disease
Chair: Dita Maixnerová (Czech Republic)

What progress has been made in understanding IgAN in children in the last decade?
Rosanna Coppo (Italy)

The challenges of designing a clinical trial in paediatric kidney disease
Louise Oni (United Kingdom)

What can CureGN tell us about IgAN in children and young adults?
Michelle Rheault (United States)

11:05–11:10 Break

Plenary Session 10
IgAN: A Global Perspective
Chair: Agnes Fogo (United States)

IgAN: A South-Asian Perspective
Suceena Alexander (India)

A South American Perspective
Hernán Trimarchi (Argentina)

Establishing a global network to promote involvement in kidney disease research
David Wheeler (United Kingdom)

12:00–12:25 Lunch Break

Free Communications 3
Chairs: Dana Rizk (United States) & Renato Monteiro (France)

Selective ETA Antagonist Atrasentan, Rapidly Reduces Albuminuria and Downregulates Intra-renal Pro-Inflammatory and Pro-Fibrotic Transcriptional Networks in the gddY Mouse Model of Spontaneous IgA Nephropathy
Andrew King (Canada)

Analysis of the effect of TRF-budesonide (Nefecon) on urinary sCD163 in patients with IgAN from the Phase 2 NEFIGAN trial
Jürgen Floege (Germany)

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VIS649, an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers: Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study
Yusuke Suzuki (Japan)

Impact of polyclonal anti-T-lymphocyte immunoglobulins on the recurrence of IgA nephropathy after kidney transplantation: The pirat study
Nicolas Maillard (France)

BAFF-dependent IgA production do not play a pivotal role in the pathogenesis of murine IgA nephropathy
Jin Sug Kim (Korea)

13:25–13:30 Break

Panel Discussion 3
Expert Panel: Where will the next key advances in our understanding of the pathogenesis of IgAN come from?
Chair: Heather Reich (Canada)

Panel members: Ali Gharavi (United States), Renato Monteiro (France), Julio Saez-Rodrigo (Germany), Lesley Inker (United States

14:30–14:35 Break
14:35–15:35 Industry Symposium 5
15:35–15:40 Break
15:40–16:00 Awards
16:00–16:15 Final word & introduction of next symposium


 All times in the symposium programme are in Central European Summer Time – CEST (UTC + 2).




Symposium Secretariat

GUARANT International spol. s r.o.
Českomoravská 19
190 00 Prague 9
Czech Republic

+420 284 001 444